drugset / Trial / NCT02532140

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime

NCT02532140

Phase 1 Completed 88 enrolled Wockhardt Quintiles, Inc. · collab
RandomizedCrossoverQuadruple-blindBasic science

Summary

• To evaluate the safety,tolerability and pharmacokinetics of single intravenous doses of WCK 5107 alone and in combination with cefepime in healthy adult human subjects.

Timeline

Start
2015-08
Primary completion
2015-11
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefepime Small molecule 2000 mg Intravenous
Subject Zidebactam Small molecule 250 mg Intravenous
Subject Zidebactam Small molecule 1000 mg Intravenous
Subject Zidebactam Small molecule 2000 mg Intravenous

Indications

No indication recorded.